Key facts: Eli Lilly's orforglipron achieves 12.4% weight loss; Zepbound surpasses Wegovy; Operating margin rises to 40.9%
I'm PortAI, I can summarize articles.
Eli Lilly's orforglipron, a daily oral GLP-1 agonist, showed 12.4% weight loss in trials. The FDA application is submitted, with a planned price of $149 per month.12Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a study, leading analysts to predict Zepbound will surpass Wegovy sales by 2025.3Eli Lilly's adjusted operating margin has risen by 20.8 percentage points over the past two years, now standing at 40.9% for the trailing 12 months, highlighting enhanced profitability.4
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments